Tobrate™ (oral tobramycin tablet) is being evaluated for its potential to treat uncomplicated urinary tract infections (uUTI), a highly prevalent infection affecting approximately 10 million women in the United States each year.
There are several antibiotics available to treat uUTI, however antibiotic resistance is a growing issue, in turn causing current uUTI treatments to become less efficacious. Tobramycin, which has minimal resistance issues, is available in a variety of dosage forms, however no oral formulation exists on the market.
An oral formulation of tobramycin offers an attractive alternative to available first-line treatments that are now less effective due to antibiotic resistance.
Tobrate is currently being evaluated in a randomized, double-blind, single ascending dose/multiple ascending dose (SAD/MAD) Phase 1 pharmacokinetic study in 24 healthy volunteers. Data from the study is expected in the first quarter of 2017.